Key result
Potential drug-drug interactions were observed in 48.84% of medication prescriptions for outpatient children with bronchopneumonia, with the majority being of moderate severity.
Why the study?
There was a lack of documentation of drug-drug interactions in the treatment of bronchopneumonia in outpatient settings.
Cross-Sectional (n=86)
No
Nearly half of pediatric outpatient prescriptions for bronchopneumonia contained potential drug-drug interactions, predominantly moderate pharmacodynamic interactions such as ephedrine and salbutamol.
Requires caution in pediatric bronchopneumonia prescribing; leaves open clinical significance of potential interactions.
Drug-drug interactions (DDIs) is defined as the alteration of efficacy and toxicity of some drugs in the presence of other drugs. In the treatments of bronchopneumonia in outpatient settings, there is a lack of documentation of DDIs. This study was aimed to observe the potential DDIs on the prescriptions of children with bronchopneumonia. An observational and cross-sectional study was conducted on outpatient children with bronchopneumonia prescriptions during 2017. Potential for DDI was identified by online drug interaction checkers. The potential DDI then classified based on its severity (minor, moderate, and major) and mechanism (pharmacokinetic and pharmacodynamic). Among 86 prescriptions analyzed, potential DDIs observed at 48.84% of it. Of that, there were 67 potential DDIs where 72.34% of it were categorized as moderate. The majority of potential DDIs was pharmacodynamic interaction (76.12%) with the most frequently involved drug pair was Ephedrine-Salbutamol (29.85%). Children outpatients with bronchopneumonia are at risk of potential DDIs, especially to minor and moderate potential DDIs. Prescriptions screening for potential DDIs followed by monitoring of therapeutical effects and associated adverse drug events will optimize patient safety.
No takes yet. Share an insight, caveat, or question.
Zulfa et al. (2020) conducted a cross-sectional in Bronchopneumonia (n=86). Bronchopneumonia medication prescriptions was evaluated on Prevalence of potential drug-drug interactions (DDIs). Potential drug-drug interactions were observed in 48.84% of medication prescriptions for outpatient children with bronchopneumonia, with the majority being of moderate severity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: